Insight Molecular Diagnostics Inc. IMDX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -60.77% | -49.28% | 115.58% | 520.87% | 316.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -60.77% | -49.28% | 115.58% | 520.87% | 316.13% |
| Cost of Revenue | -54.70% | -45.30% | 66.86% | 234.40% | 168.69% |
| Gross Profit | -65.69% | -52.64% | 177.54% | 1,985.34% | 649.04% |
| SG&A Expenses | 18.57% | 20.72% | 19.99% | 26.15% | 27.88% |
| Depreciation & Amortization | -100.00% | -100.00% | -100.00% | -75.00% | -50.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.52% | 35.68% | 37.83% | 29.09% | 28.05% |
| Operating Income | -49.74% | -49.65% | -31.54% | -13.85% | -14.43% |
| Income Before Tax | 22.17% | 17.81% | 17.21% | -40.87% | -75.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 22.17% | 17.81% | 17.21% | -40.87% | -75.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.17% | 17.81% | 17.21% | -40.87% | -75.48% |
| EBIT | -49.74% | -49.65% | -31.54% | -13.85% | -14.43% |
| EBITDA | -51.85% | -50.74% | -30.89% | -10.66% | -12.76% |
| EPS Basic | 57.26% | 57.96% | 63.20% | 36.09% | 18.32% |
| Normalized Basic EPS | 11.71% | 26.99% | 48.47% | 54.59% | 47.46% |
| EPS Diluted | 57.26% | 57.96% | 63.20% | 36.09% | 18.32% |
| Normalized Diluted EPS | 11.71% | 26.99% | 48.47% | 54.59% | 47.46% |
| Average Basic Shares Outstanding | 52.42% | 87.54% | 133.23% | 148.49% | 135.85% |
| Average Diluted Shares Outstanding | 52.42% | 87.54% | 133.23% | 148.49% | 135.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |